Metabolic syndrome, its phenotypes, and insulin resistance by HOMA-IR;Síndrome metabólica, seus fenótipos e resistência à insulina pelo HOMA-RI

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 9, 2007, Pages 1506-1515

  De Oliveira, Ernesto P ^a   De Lima, Maria Das Dores A ^a   De Souza, Mirabeau Levi A ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Diagnosis; HOMA (homeostatic model assessment); Insulin resistance; Metabolic syndrome X

Indexed keywords

EID: 38849135861     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000900014     Document Type: Article

References (40)

1. Hopkins PN, Williams RR. A survey of 246 suggested coronary risk factors. Atherosclerosis 1981;40:1-52.
2. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
3. Kaplan NM. The delay quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989;149:1514-20.
4. National Institutes of Health. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
5. Stern SE, Williams K, Ferrannini E, DeFronzo RA, Bogardus C, Stern MP. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005;54:333-9.
6. American College of Endocrinology. Executive summary of the Position statement on the insulin resistance syndrome. Endocr Pract 2003;9(3):237-9.
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
8. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002;19:527-34.
9. Monzillo LU, Handy O. Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev 2003;61(12):397-412.
10. Wallace TM, Levy J, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27(6):1487-95.
11. Oliveira EP, Souza MLA, Lima MDA. Índice HOMA (homeostasis model assessment) na prática clínica: uma revisão. J Bras Patol Med Lab 2005;41(4):237-43.
12. Oliveira EP, Souza MLA, Lima MDA. Prevalência de síndrome metabólica em uma área rural do semi-árido baiano. Arq Bras Endocrinol Metab 2006;50(3):456-65.
13. th ed. USA: Appleton & Lange, 1994. pp. 571-634.
14. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16(5):442-3.
15. Grundy SM. Metabolic syndrome: part I. Endocrinol Metab Clin North Am 2004;33:IX-XI.
16. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts and different goals. Endocrinol Metab Clin North Am 2004;33:283-303.
17. Ford ES, Giles WH. The comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003;26:575-81.
18. Meigs JB, Wilson PWF, Nathan DM, D'Agostino RB, Williams K, Haffner SM. Prevalence and Characteristics of the metabolic syndrome in the San Antonio Heart and Framingham offspring studies. Diabetes 2003;52:2160-7.
19. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W, et al. Insulin resistance, the metabolic syndrome and risk of incident cardiovascular disease in nondiabetic American Indians. Diabetes Care 2003;26:861-7.
20. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H. The metabolic syndrome, insulin resistance and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 2005;90(10):5698-703.
21. Tipene-Leach D, Pahau H, Joseph N, Coppell K, McAuley K, Booker C, et al. Insulin resistance in a rural Maori community. N Z Med J 2004;117(1207):U1208.
22. McAuley KA, Williams SM, Mann J, Walker RJ, Lewis-Barned NJ, Temple LA, et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001;24:460-4.
23. Bustos P, Amigo H, Arteaga A, Acosta AM, Rona R. Factores de riesgo de enfermedad cardiovascular en adultos jóvenes. Rev Méd Chile 2003;131:973-80.
24. Jaber LA, Brown MB, Hammad A, Zhu Q, Herman WH. The prevalence of the metabolic syndrome among Arab Americans. Diabetes Care 2004;27(1):234-8.
25. Bergman RN, Zaccaro DJ, Watanabe RM, Haffner SM, Saad MF, Morris JM, et al. Minimal model-based insulin sensitivity has greater heritability and a different genetic basis than the homeostasis model assessment or fast insulin. Diabetes 2003;52:2168-74.
26. Gokcel A, Baltali M, Tarim E, Bagis T, Gumurdulu Y, Karakose H, et al. Detection of insulin resistance in Turkish adult: a hospital-based study. Diabetes Obes Metab 2003;5:126-30.
27. Bravata DM, Wells CK, Concato J, Kernan WN, Brass LM, Gulanski BI. Two measures of insulin sensitivity provided similar information in a U.S. population. J Clin Epidemiol 2004;57:1214-7.
28. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004;33:351-75.
29. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension and cardiovascular disease. J Clin Endocrinol Metab 2003;88(6):2399-403.
30. Assmann G, Nofer JR, Schulte H. Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinol Metab Clin North Am 2004;33:377-92.
31. Jeffs JAR, Godsland IF, Johnston DG. Less than 50% of variation in HDL cholesterol between and within individuals is explained by estabilished predictors. Atherosclerosis 2005;184(1):178-87.
32. Park YW, Zhu S, Palaniappan L Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988-1994. Arch Intern Med 2003;163:427-36.
33. Natali A, Ferrannini E. Hypertension, insulin resistance and the metabolic syndrome. Endocrinol Metab Clin North Am 2004;33:417-29.
34. Mohteshamzadeh M, Wilkinson R, Thomas SHL. Insulin resistance in men with treated hypertension at increased risk for cardiovascular disease: results of a 3-year study. Am J Hypertens 2005;18:452-6.
35. Taniguchi A, Nakai Y, Sakai M, Yoshii S, Hamanaka D, Hatae Y, et al. Relationship of regional adiposity to insulin resistance and serum triglyceride levels in non-obese Japanese type 2 diabetic patients. Metabolism 2002;51(5):544-8.
36. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003;17:305-22.
37. Stumvoll M, Häring H. Insulin resistance and insulin sensitizers. Horm Res 2001;55(suppl 2):3-13.
38. Füllert S, Schneider F, Haak E, Rau H, Badenhoop K, Lubben G, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002;87(12):5503-6.
39. Goldstein BJ. Insulin resistance as the core defect in type 2 diabetes mellitus. Am J Cardiol 2002;90(5A):3G-10G.
40. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med 2005;142:611-9.